US govt to invest over $3 billion for Covid-19 antiviral medicines

Representative Image

The US government is investing more than $3 billion to accelerate the development and manufacturing of antiviral medicines to treat Covid-19, according to a statement by the Department of Health and Human Services (HHS).

The plan, called the Antiviral Program for Pandemics, will respond to the urgent need for the antivirals by spurring the availability of medicines to prevent serious illness and save lives, Xinhua news agency quoted the statement as saying on Friday.

This plan will support research to identify and accelerate availability of breakthrough treatment options.

It also will build sustainable platforms for developing antivirals for other viruses with pandemic potential, said the HHS.

The plan provides more than $300 million for research and lab support; nearly $1 billion for preclinical and clinical evaluation; and nearly $700 million for development and manufacturing through the National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA),the statement added.

Identifying effective treatment options to prevent people diagnosed with Covid-19 from progressing to serious illness and death are vitally important, even as hundreds of millions of Americans get vaccinated against the disease and cases, hospitalisations and death rates continue to fall, experts have said.

Highly effective oral antiviral medicines that can be taken at home early in the course of infection, similar to antiviral treatment for influenza, would save lives and prevent overwhelming surges in hospitalizations, according to the HHS.

"New antivirals that prevent serious Covid-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives," said NIAID Director Anthony Fauci.

"Throughout this public health emergency, we have worked with industry to develop treatments to reduce severe illness, hospitalisations, and deaths, and this proposal will help us go even further to accelerate and deliver more safe and effective treatments that are easy to administer," said BARDA Director Gary Disbrow.

Currently, a total of 19 therapeutic agents have been prioritised for testing in rigorous clinical trials for outpatients and inpatients with Covid-19, according to the HHS.

Last week, President Joe Biden's administration announced that it will procure approximately 1.7 million courses of an investigational antiviral treatment, molnupiravir (MK-4482), for Covid-19 from Merck, pending approval from the Food and Drug Administration.

--IANS

ksk/

 


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel